Patents for A61K 39 - Medicinal preparations containing antigens or antibodies (182,248) |
---|
10/09/2014 | US20140302018 Treatment of diffuse large-cell lymphoma with anti-cd20 antibody |
10/09/2014 | US20140302017 Treating skin cancer |
10/09/2014 | US20140302014 Methods for the treatment of cancer using coenzyme q10 combination therapies |
10/09/2014 | US20140302012 Combination Therapies for Treating Hematologic Malignancies Using Pyridopyrimidinone Inhibitors of PI3K/mTOR with Bendamustine and/or Rituximab |
10/09/2014 | US20140302011 Compositions including triciribine and trastuzumab and methods of use thereof |
10/09/2014 | US20140302009 Medicinal Agent for Prevention or Treatment of Diseases Associated with Intraocular Neovascularization and/or Intraocular Vascular Hyperpermeability |
10/09/2014 | US20140301982 Complement antagonists and uses thereof |
10/09/2014 | US20140301973 Combination therapies for treating type 1 diabetes |
10/09/2014 | US20140301953 Allergens from insects |
10/09/2014 | US20140301951 Porous nanoparticle supported lipid nanostructures |
10/09/2014 | US20140301945 Human anti-sod1 antibodies |
10/08/2014 | EP2787081A1 Drug containing carrier into cell for forming immune complex |
10/08/2014 | EP2787078A1 Antigen-binding molecule having regulated conjugation between heavy-chain and light-chain |
10/08/2014 | EP2787007A2 Subcutaneously administered ANTI-IL-6 receptor antibody |
10/08/2014 | EP2786767A2 Real-time detection of influenza virus |
10/08/2014 | EP2786765A2 Composition for combination therapy comprising an anti-C-met antibody and a FGFR inhibitor |
10/08/2014 | EP2786764A2 Combination therapy using anti-c-met antibody and sorafenib |
10/08/2014 | EP2786763A1 Capsule composition for use as immunogen against Campylobacter jejuni |
10/08/2014 | EP2786762A2 Covalent diabodies and uses thereof |
10/08/2014 | EP2786746A1 Stabilizing a Liquid Formulation Containing a Protein Drug |
10/08/2014 | EP2785842A1 Hpv chimaeric particle |
10/08/2014 | EP2785743A1 Anti-ceacam1 recombinant antibodies for cancer therapy |
10/08/2014 | EP2785742A1 Anti-kdr antibodies and methods of use |
10/08/2014 | EP2785739A1 Improving trabeculectomy outcome |
10/08/2014 | EP2785738A1 Anti-npy and pyy antibodies and uses thereof |
10/08/2014 | EP2785382A1 Multivalent antibody complexes targeting igf-1r show potent toxicity against solid tumors |
10/08/2014 | EP2785378A1 Methods and compositions for increasing arylsulfatase a activity in the cns |
10/08/2014 | EP2785377A1 A method to enhance cognition |
10/08/2014 | EP2785376A1 Anti-glucosaminidase passive immunization for staphylococcus aureus infections |
10/08/2014 | EP2785375A1 Anti-pd-l1 antibodies and uses thereof |
10/08/2014 | EP2785374A2 Recombinant gallid herpesvirus 3 (mdv serotype 2) vectors expressing antigens of avian pathogens and uses thereof |
10/08/2014 | EP2785373A1 Recombinant hvt vectors expressing antigens of avian pathogens and uses thereof |
10/08/2014 | EP2785372A1 Influenza virus vaccines and uses thereof |
10/08/2014 | EP2785371A1 Polypeptide adjuvant |
10/08/2014 | EP2785370A2 Vaccine for falciparum malaria |
10/08/2014 | EP2785369A1 Immunogenic plasmodium falciparum antigen compositions and uses thereof |
10/08/2014 | EP2785368A1 Immunogenic composition comprising panton-valentine leukocidin (pvl) derived polypeptides |
10/07/2014 | US8853382 Expression of antibody or a fragment thereof in lactobacillus |
10/07/2014 | US8853379 Chimeric poly peptides and the therapeutic use thereof against a flaviviridae infection |
10/07/2014 | US8853371 Process for preparing unaggregated antibody Fc domains |
10/07/2014 | US8853369 Anti-Axl antibodies and methods of use |
10/07/2014 | US8853368 Human antibodies against human glycoprotein VI and their use |
10/07/2014 | US8853366 Binding domain-immunoglobulin fusion proteins |
10/07/2014 | US8853365 Dual variable domain immunnoglobulins and uses thereof |
10/07/2014 | US8853364 Prostate stem cell antigen (PSCA) variants and subsequences thereof |
10/07/2014 | US8853363 Substance binding human IgG Fc receptor IIb (FcγRIIb) |
10/07/2014 | US8853360 Engineered botulinum neurotoxin C1 with selective substrate specificity |
10/07/2014 | US8853283 Stable crystal modifications of DOTAP chloride |
10/07/2014 | US8853159 GLP-1 Fusion Peptides |
10/07/2014 | US8853146 Hapten compounds and compositions and uses thereof |
10/07/2014 | US8852914 Flavivirus vaccines |
10/07/2014 | US8852887 Antibodies against human tweak and uses thereof |
10/07/2014 | US8852874 Anti-amyloid β activity of intravenous immunoglobulin (IVIG) in vitro |
10/07/2014 | US8852871 Humanized anti-IL-10 antibodies for the treatment of systemic lupus erythematosus (SLE) |
10/07/2014 | US8852860 Sperm-specific cation channel, CatSper1 and uses therefor |
10/07/2014 | US8852613 One dose vaccination against Mycoplasma infections of pigs |
10/07/2014 | US8852612 Universal carrier for targeting molecules to Gb3 receptor expressing cells |
10/07/2014 | US8852611 Compositions and methods for vaccinating against HSV-2 |
10/07/2014 | US8852610 Compositions and methods for vaccinating against HSV-2 |
10/07/2014 | US8852609 Consensus sequences of chikungunya viral proteins, nucleic acid molecules encoding the same, and compositions and methods for using the same |
10/07/2014 | US8852608 Antibodies against and methods for producing vaccines for respiratory syncytial virus |
10/07/2014 | US8852607 Excipients for use in adeno-associated virus pharmaceutical formulations, and pharmaceutical formulations made therewith |
10/07/2014 | US8852606 Capsular polysaccharide solubilisation and combination vaccines |
10/07/2014 | US8852605 Vibrio cholerae O139 conjugate vaccines |
10/07/2014 | US8852604 Multiepitope vaccine for Her2/neu-associated cancers |
10/07/2014 | US8852603 Inhibition of secretion from non-neuronal cells |
10/07/2014 | US8852602 Immunological herpes simplex virus antigens and methods for use thereof |
10/07/2014 | US8852601 Method of stimulating growth and resistance to diseases of aquatic organisms |
10/07/2014 | US8852600 Codon-optimized DNA molecules encoding the receptor binding domains of Clostridium difficile toxins A and B, and methods of use thereof |
10/07/2014 | US8852599 Immunoconjugates, compositions for making them, and methods of making and use |
10/07/2014 | US8852598 Puumala virus full-length M segment-based DNA vaccines |
10/07/2014 | US8852597 Anti-CD154 antibodies having impaired FcR binding and/or complement binding properties |
10/07/2014 | US8852596 Detection of Giardia lamblia trophozoites and cysts and protection against G. lamblia infection |
10/07/2014 | US8852595 Human binding molecules capable of binding to and neutralizing influenza B viruses and uses thereof |
10/07/2014 | US8852594 Compositions and methods for the therapy and diagnosis of cytomegalovirus infections |
10/07/2014 | US8852593 Antagonist antibodies and their fab fragments against GPVI and uses thereof |
10/07/2014 | US8852592 Systems and methods for anti-PAX8 antibodies |
10/07/2014 | US8852591 Combination of BLyS and/or APRIL inhibition and immunosuppressants for treatment of autoimmune disease |
10/07/2014 | US8852590 Compositions and methods for treating cancer |
10/07/2014 | US8852589 Antibodies against IL-17BR |
10/07/2014 | US8852588 Treating allergic airway disorders using anti-IL-20 receptor antibodies |
10/07/2014 | US8852587 Anti-prion protein antibody fragment |
10/07/2014 | US8852586 Fc variants with altered binding to FcRn |
10/07/2014 | US8852585 Method of treatment and prophylaxis of diseases related to amyloid deposition using IgM |
10/07/2014 | US8852577 Recombinant proteins of Parapoxvirus ovis and pharmaceutical compositions therefrom |
10/07/2014 | US8852551 Methods to impair hematologic cancer progenitor cells and compounds related thereto |
10/02/2014 | WO2014160987A2 Vaccines comprising leishmania polypeptides for the treatment and diagnosis of leishmaniasis |
10/02/2014 | WO2014160985A2 Vaccines comprising leishmania polypeptides for the treatment and diagnosis of leishmaniasis |
10/02/2014 | WO2014160958A1 Compositions and methods for increasing the serum half-life of a therapeutic agent targeting complement c5 |
10/02/2014 | WO2014160932A1 Compositions and methods for treating osteolytic bone disorders |
10/02/2014 | WO2014160902A1 Directed immune stimulation |
10/02/2014 | WO2014160747A2 Compositions and methods for the treatment or prevention of human immunodeficiency virus infection |
10/02/2014 | WO2014160497A1 Formulations with reduced oxidation |
10/02/2014 | WO2014160495A1 Formulations with reduced oxidation |
10/02/2014 | WO2014160490A1 Antibody formulations |
10/02/2014 | WO2014160463A1 Prefusion rsv f proteins and their use |
10/02/2014 | WO2014160336A1 METHODS OF ADMINISTERING IgG1 ANTIBODIES AND METHODS OF SUPPRESSING ANGIOGENESIS |
10/02/2014 | WO2014160318A1 Endogenous vaccine for cancer and infectious diseases |
10/02/2014 | WO2014160183A1 Methods for modulating chemotherapeutic cytotoxicity |
10/02/2014 | WO2014160171A2 Immunogenic peptide conjugate and method for inducing an anti-influenza therapeutic antibody response therewith |